BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 36005485)

  • 1. Heteronemin and Tetrac Induce Anti-Proliferation by Blocking EGFR-Mediated Signaling in Colorectal Cancer Cells.
    Unson S; Chang TC; Yang YN; Wang SH; Huang CH; Crawford DR; Huang HM; Li ZL; Lin HY; Whang-Peng J; Wang K; Davis PJ; Li WS
    Mar Drugs; 2022 Jul; 20(8):. PubMed ID: 36005485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined Treatment of Heteronemin and Tetrac Induces Antiproliferation in Oral Cancer Cells.
    Huang CH; Huang TY; Chang WJ; Pan YS; Chu HR; Li ZL; Unson S; Chin YT; Lin CY; Huang HM; Hsiung CN; Gionfra F; De Vito P; Pedersen JZ; Incerpi S; Chen YR; Lee SY; Lin HY; Davis PJ; Whang-Peng J; Wang K
    Mar Drugs; 2020 Jul; 18(7):. PubMed ID: 32630719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heteronemin and tetrac derivatives suppress non-small cell lung cancer growth via ERK1/2 inhibition.
    Chung CC; Huang TY; Chu HR; De Luca R; Candelotti E; Huang CH; Yang YSH; Incerpi S; Pedersen JZ; Lin CY; Huang HM; Lee SY; Li ZL; ChangOu CA; Li WS; Davis PJ; Lin HY; Whang-Peng J; Wang K
    Food Chem Toxicol; 2022 Mar; 161():112850. PubMed ID: 35151786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NDAT Targets PI3K-Mediated PD-L1 Upregulation to Reduce Proliferation in Gefitinib-Resistant Colorectal Cancer.
    Huang TY; Chang TC; Chin YT; Pan YS; Chang WJ; Liu FC; Hastuti ED; Chiu SJ; Wang SH; Changou CA; Li ZL; Chen YR; Chu HR; Shih YJ; Cheng RH; Wu A; Lin HY; Wang K; Whang-Peng J; Mousa SA; Davis PJ
    Cells; 2020 Aug; 9(8):. PubMed ID: 32756527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The power of heteronemin in cancers.
    Wang K; Chen YF; Yang YSH; Huang HM; Lee SY; Shih YJ; Li ZL; Whang-Peng J; Lin HY; Davis PJ
    J Biomed Sci; 2022 Jun; 29(1):41. PubMed ID: 35705962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The combination of tetraiodothyroacetic acid and cetuximab inhibits cell proliferation in colorectal cancers with different K-ras status.
    Lee YS; Chin YT; Yang YSH; Wei PL; Wu HC; Shih A; Lu YT; Pedersen JZ; Incerpi S; Liu LF; Lin HY; Davis PJ
    Steroids; 2016 Jul; 111():63-70. PubMed ID: 26980146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
    Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
    J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer.
    Ye H; Liu Y; Wu K; Luo H; Cui L
    Cell Commun Signal; 2020 Jul; 18(1):115. PubMed ID: 32703218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
    Chen P; Li X; Zhang R; Liu S; Xiang Y; Zhang M; Chen X; Pan T; Yan L; Feng J; Duan T; Wang D; Chen B; Jin T; Wang W; Chen L; Huang X; Zhang W; Sun Y; Li G; Kong L; Chen X; Li Y; Yang Z; Zhang Q; Zhuo L; Sui X; Xie T
    Theranostics; 2020; 10(11):5107-5119. PubMed ID: 32308771
    [No Abstract]   [Full Text] [Related]  

  • 10. A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab.
    Lee SK; Cho YH; Cha PH; Yoon JS; Ro EJ; Jeong WJ; Park J; Kim H; Il Kim T; Min DS; Han G; Choi KY
    Exp Mol Med; 2018 Nov; 50(11):1-12. PubMed ID: 30459318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feedback activation of EGFR/wild-type RAS signaling axis limits KRAS
    Feng J; Hu Z; Xia X; Liu X; Lian Z; Wang H; Wang L; Wang C; Zhang X; Pang X
    Oncogene; 2023 May; 42(20):1620-1633. PubMed ID: 37020035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts.
    Lee HW; Son E; Lee K; Lee Y; Kim Y; Lee JC; Lim Y; Hur M; Kim D; Nam DH
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31771279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
    Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systems mechanism for KRAS mutant allele-specific responses to targeted therapy.
    McFall T; Diedrich JK; Mengistu M; Littlechild SL; Paskvan KV; Sisk-Hackworth L; Moresco JJ; Shaw AS; Stites EC
    Sci Signal; 2019 Sep; 12(600):. PubMed ID: 31551296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of thyroid hormone-integrin αvβ3-signal and therapeutic strategies in colorectal cancers.
    Yang YSH; Ko PJ; Pan YS; Lin HY; Whang-Peng J; Davis PJ; Wang K
    J Biomed Sci; 2021 Apr; 28(1):24. PubMed ID: 33827580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Krill oil extract inhibits the migration of human colorectal cancer cells and down-regulates EGFR signalling and PD-L1 expression.
    Jayathilake AG; Veale MF; Luwor RB; Nurgali K; Su XQ
    BMC Complement Med Ther; 2020 Dec; 20(1):372. PubMed ID: 33287803
    [